v3.26.1
Share Capital - Option Transaction (Details)
 6 Months Ended 12 Months Ended
Sep. 25, 2023
Equityinstruments
$ / shares
Dec. 31, 2024
Equityinstruments
$ / shares
Dec. 31, 2025
Equityinstruments
$ / shares
Number of options      
Balance at beginning of period (in shares) | Equityinstruments   9,070,000 10,647,246
Options granted (in shares) | Equityinstruments 1,000,000 1,927,246 2,806,452
Options exercised (in shares) | Equityinstruments   (450,000) (1,250,000)
Options modified (in shares) | Equityinstruments [1]   1,000,000  
Options expired (in shares) | Equityinstruments   (900,000) (525,000)
Balance at end of period (in shares) | Equityinstruments   10,647,246 11,678,698
Weighted average exercise price      
Balance at beginning of period (in USD per share) | $ / shares   $ 3.43 $ 2.8
Options granted (in USD per share) | $ / shares $ 2.97 1.26 1.54
Options exercised (in USD per share) | $ / shares   1.06 2.44
Options modified (in USD per share) | $ / shares [1]   1.36  
Options expired (in USD per share) | $ / shares   3.27 5.83
Balance at end of period (in USD per share) | $ / shares   $ 2.8 $ 2.4
[1] On September 1, 2024, 2,000,000 Options were granted to a corporation controlled by an officer of the Company, with an exercise price of $1.36 for a period of 5 years. 666,667 Options vested on September 1, 2024, 666,667 Options vested on September 1, 2025, and 666,666 Options will vest on September 1, 2026. These Options were designated as a replacement for 1,000,000 Options with an exercise price of $2.97 previously granted on September 25, 2023. The newly issued Options are treated as a modification of the original Options. The Company will recognize share-based compensation expense for any incremental fair value, as determined immediately before the modification, in addition to the grant-date fair value of the original award.